Compare Apple Inc (AAPL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.

The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.